- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02351011
Human Autologous MSCs for the Treatment of Mid to Late Stage Knee OA
Human Autologous Mesenchymal Stromal Cells for the Treatment of Mid to Late Stage Knee Osteoarthritis
Osteoarthritis (OA) is one of the most common forms of arthritis. It is a lasting condition in which the material that cushions the joints, called cartilage, breaks down. This causes the bones to rub against each other, causing inflammation, stiffness, pain and loss of joint movement. Currently, there are few effective treatments available for patients suffering from OA.
Mesenchymal stem cells (MSCs) are cells that have the ability to self-regenerate, which means they have the ability to make copies of themselves and to turn into other kinds of cells (e.g. cartilage cells). Stem cell science shows much promise for the future treatment of osteoarthritis, but much of the research is still in the early stages. In this study, researchers want to determine the safety of MSCs that a patient can tolerate without causing side effects. This will be done by starting at a low dose of MSCs and moving on to the next higher dose level provided there are no safety concerns. Researchers will also be looking at the function of the knee over time, which may give them some insight on the usefulness of MSCs as a treatment option.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The trial is a non-randomized, open-label, dose escalation phase I/II clinical trial. A total of 12 participants will be enrolled - patients will be treated in cohorts of 3 to determine the safety and preliminary efficacy of autologous, ex-vivo expanded bone-marrow derived MSC injected into the knee joint in patients with moderate to advanced knee osteoarthritis.
A minimum of three evaluable patients will be entered at each dose level until the maximum tolerated dose (MTD) is reached. Toxicity will be evaluated and graded according to the Common Terminology Criteria (CTC) for Adverse Events, as Grade 3-4. If a patient is discontinued due to a grade 3 or 4 adverse event (i.e. dose-limiting toxicity, DLT), an additional patient will be enrolled at the same dose level to ensure that a minimum of 3 patients are evaluated. If 0/3 patients experience dose-limiting (DLT) at a given dose level, then the dose will be escalated for next cohort of 3 patients. If 1/3 patients experience DLT at a given dose level, then an additional 3 patients will be treated at that dose level. If no other patient experiences a DLT, dose escalation will continue. If DLT occurs in 2/3 or 2/6 patients, dose escalation will stop and the prior dose level will be declared the MTD for the MSC cell infusions in this study.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M5T 2S8
- Toronto Western Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients between 40-65 years of age with symptomatic moderate to severe (Kellgren-Lawrence III or IV) primary osteoarthritis of the knee
- Failed conservative management including physical therapy, bracing and/or oral anti-inflammatories for a minimum of six months
- No history of prior intra-articular cortisone, hyaluronic acid, or platelet-rich plasma injection within the previous six months
- No history of prior arthroscopic knee surgery or open knee surgery on the ipsilateral side within the past year
- Adequate bone marrow, liver, and renal functions
- Body weight >40 kg
- Body Mass Index <30
- Negative for (HIV, HTLV1&2, Hep A, B, C, syphilis) infection as determined by approved serological testing
- Negative for pregnancy as determined by a serum pregnancy test. Females of childbearing potential will be required to practice abstinence or use an effective form of contraception for 12 months following their MSC injection.
- Fluid > 1 cm within the lateral recess of the suprapatellar pouch at the level of the superior pole of the patella with the knee extended.
Exclusion Criteria:
- Patients with clinically unstable knee due to the presence of a complete anterior cruciate ligament, posterior cruciate ligament, medial collateral ligament and/or posterolateral corner tear
- Patients with varus or valgus malalignment >5 degrees as measured by 4 foot standing antero-posterior radiographs
- Patients with a history of a previous subtotal medial or lateral meniscectomy
- Patients with a history of septic arthritis in the affected joint
- Patients with a history of a prior intra-articular knee fracture
- Severe bleeding diathesis
- Contraindication to bone marrow aspiration and/or biopsy
- Active infection
- Bone marrow failure
- Cytopenia
- Patients who have previously received radiotherapy to the pelvis
- Patients who have been on chemotherapy from within a year of the date of informed
- Patients with positive serological test for (HIV, HTLV1&2, Hep A, B, C, syphilis)
- Pregnancy or risk of pregnancy (this includes participants that are not willing to practice active contraception for the duration of the study)
- Patients with unforeseen conditions that are deemed unsafe or inappropriate for the study (e.g. patients who are claustrophobic and cannot undergo an MRI) as per the discretion of the principal investigator
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort 1
1 x 10^6 MSCs
|
Autologous, bone-marrow derived MSCs
Other Names:
|
Experimental: Cohort 2
10 x 10^6 MSCs
|
Autologous, bone-marrow derived MSCs
Other Names:
|
Experimental: Cohort 3
50 x 10^6 MSCs
|
Autologous, bone-marrow derived MSCs
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety as determined by the occurrence of local and systemic adverse events and/or serious adverse events.
Time Frame: 1 to 5 years
|
Safety as determined by the occurrence of local and systemic adverse events and/or serious adverse events.
|
1 to 5 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Knee Injury and Osteoarthritis Outcome Score (KOOS)
Time Frame: 1 year
|
Knee-joint specific function
|
1 year
|
Marx Activity Scale (Patient-reported activity)
Time Frame: 1 year
|
Patient-reported activity
|
1 year
|
Short-Form 36 (Health-related quality of life)
Time Frame: 1 year
|
Health-related quality of life
|
1 year
|
Whole Organ MRI Score (WORMS), Gadolinium-enhanced MRI, T2 Mapping (To assess joint structure, inflammation, and cartilage status over time)
Time Frame: 1 year
|
To assess joint structure, inflammation, and cartilage status over time
|
1 year
|
Cartilage oligomeric matrix protein (COMP)
Time Frame: 1 year
|
Serum marker of cartilage metabolism
|
1 year
|
Hyaluronic acid (HA)
Time Frame: 1 year
|
Serum pro-inflammatory marker
|
1 year
|
C-terminal telopeptide of type II collagen (CTXII)
Time Frame: 1 year
|
Urine marker of cartilage metabolism
|
1 year
|
Types I and II collagen cleavage (C1,2C)
Time Frame: 1 year
|
Urine marker of cartilage metabolism
|
1 year
|
Type II collagen cleavage (C2C)
Time Frame: 1 year
|
Urine marker of cartilage metabolism
|
1 year
|
IL-6/TNFα/IL-15
Time Frame: 1 year
|
Synovial fluid pro-inflammatory markers
|
1 year
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Jas Chahal, MD, MSc, Arthritis Program, Toronto Western Hospital
- Principal Investigator: Sowmya Viswanathan, PhD, Arthritis Program, Toronto Western Hospital & Philip S. Orsino Facility for Cell Therapy
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MSC-001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Osteoarthritis of Knee
-
Joseph E. BroylesCompletedDegenerative Lesion of Articular Cartilage of Knee | Degeneration; Articular Cartilage, Knee | Unilateral Primary Osteoarthritis of Knee | Osteoarthritis Knee
-
CrystalGenomics, Inc.CompletedLocalized Primary Osteoarthritis of Hip | Localized Primary Osteoarthritis of KneeKorea, Republic of
-
Ottawa Hospital Research InstituteCompleted
-
zhoupingBeijing Friendship Hospital; Beijing Jishuitan HospitalUnknownOsteoarthritis Of KneeChina
-
Universidade Nova de LisboaHospital de Santa Maria, Portugal; NOVA Medical School; Hospital de Egas Moniz; Instituto de Medicina Molecular João Lobo Antunes and other collaboratorsUnknown
-
Hospices Civils de LyonSmith & Nephew, Inc.Completed
-
First Affiliated Hospital of Harbin Medical UniversityShanghai Baiying Medical Technology Co., Ltd.UnknownOsteoarthritis Of KneeChina
-
Stempeutics Research Pvt LtdStempeutics Research Malaysia SDN BHDCompleted
-
Government Medical College, BhavnagarCompletedOsteoarthritis of Knee JointIndia
-
Barbara A RakelCompletedUnilateral Primary Osteoarthritis of Knee | Primary Osteoarthritis of Knee NosUnited States
Clinical Trials on 1 x 10^6 MSCs
-
The University of Texas Health Science Center,...CompletedParkinson's DiseaseUnited States
-
Celularity IncorporatedCompletedDiabetic Foot | Peripheral Arterial DiseaseUnited States
-
Celularity IncorporatedTerminatedDiabetic Foot | Peripheral Arterial DiseaseUnited States
-
PT. Prodia Stem Cell IndonesiaRecruitingRetinitis PigmentosaIndonesia
-
Medical College of WisconsinNot yet recruiting
-
MeiraGTx UK II LtdCompletedHead and Neck Cancer | Radiation-Induced Parotid Gland Hypofunction | Xerostomia Due to RadiotherapyUnited States, Canada
-
Baylor College of MedicineThe Methodist Hospital Research InstituteRecruitingEBV-Related Hodgkin Lymphoma | EBV Related Non-Hodgkin's Lymphoma | EBV-Related Lymphoproliferative DisorderUnited States
-
University of OxfordCompleted
-
Beijing Boren HospitalRecruitingAcute Myeloid LeukemiaChina
-
Emergent BioSolutionsCompleted